Your session is about to expire
← Back to Search
Resistance Exercise
Resistance Exercise for Glioblastoma (RESIST Trial)
N/A
Waitlist Available
Led By Scott Grandy, PhD
Research Sponsored by Nova Scotia Health Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Received any dose of DEX
Histologically confirmed diagnosis of either primary or secondary GBM
Timeline
Screening 3 weeks
Treatment Varies
Follow Up captured over the 12-week study period
Awards & highlights
RESIST Trial Summary
This trial will explore the effects of a circuit-based resistance training program on quality of life for patients with glioblastoma.
Who is the study for?
This trial is for English-speaking glioblastoma patients who can travel to Halifax, have a doctor's approval, and are physically able to do daily tasks (KPS >70). They must have started steroid treatment. It's not for those with unstable heart/lung disease, exercise-limiting injuries or diseases, uncontrolled seizures affecting awareness, or major cognitive issues.Check my eligibility
What is being tested?
The study tests how well a tailored circuit-based resistance exercise program helps glioblastoma survivors with their functional fitness and overall quality of life while they're receiving active treatment for their condition.See study design
What are the potential side effects?
While the trial focuses on exercise which typically has benefits like improved strength and endurance, potential side effects may include muscle soreness, fatigue, and an increased risk of injury if exercises are performed improperly.
RESIST Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have taken DEX medication.
Select...
My diagnosis is glioblastoma (GBM).
Select...
I am able to care for myself and perform normal activities with minimal assistance.
RESIST Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ captured over the 12-week study period
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~captured over the 12-week study period
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Functional Performance
Grip strength
Secondary outcome measures
Aerobic fitness
Body Mass Index (BMI)
Body composition and Muscle Mass
+8 moreOther outcome measures
Study Feasibility - Participant Accrual
Study Feasibility - Participant Adherence
Study Feasibility - Participant Attrition
+1 moreRESIST Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Exercise InterventionExperimental Treatment1 Intervention
12-week circuit-based resistance exercise
Group II: Wait-list ControlActive Control1 Intervention
Standard of care wait-list control group
Find a Location
Who is running the clinical trial?
Nova Scotia Health AuthorityLead Sponsor
257 Previous Clinical Trials
83,790 Total Patients Enrolled
Canadian Cancer Society (CCS)OTHER
78 Previous Clinical Trials
37,721 Total Patients Enrolled
2 Trials studying Glioblastoma
99 Patients Enrolled for Glioblastoma
Scott Grandy, PhDPrincipal InvestigatorDahousie University and Nova Scotia Health Authority
2 Previous Clinical Trials
120 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have heart or lung conditions that prevent me from safely exercising.I have taken DEX medication.My diagnosis is glioblastoma (GBM).I experience seizures that I cannot control and make me lose awareness.I have significant difficulties with thinking or memory.I am willing to travel to Halifax for the trial.I am able to care for myself and perform normal activities with minimal assistance.
Research Study Groups:
This trial has the following groups:- Group 1: Exercise Intervention
- Group 2: Wait-list Control
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What are the main goals of this research project?
"This clinical trial's primary metric of progress is a change in Functional Performance measured over 12 weeks. Secondary objectives include an evaluation of Cognitive Functioning 1 using Trail Making Test-B, Cognitive Functioning 2 via Hopkins Verbal Learning Test-Revised for Memory recall and recognition scores, and the General Health Visual Analog Scale from EuroQol (0 to 100; lower score indicates worse health)."
Answered by AI
Are there any vacancies available in this clinical trial?
"Unfortunately, this clinical trial is not currently accepting participants. Despite that fact, the study which was first posted on March 1st 2022 and last modified April 4th 2022 has 798 other counterparts actively recruiting patients."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger